Drug maker SynCore Biotechnology Co (杏國) is likely to swing into the black in 2020 after it launches its new drug for treating triple-negative breast cancer, Jih Sun Securities Investment Consulting Co (日盛投顧) said.
The company’s breast cancer drug SB05 (Endo-TAG 1), which it acquired from German-based MediGene AG last year, is currently under phase three clinical trials in Belgium and might enter phase three clinical trials in Australia soon, Jih Sun Securities analyst Chang Li-chun (張立群) said in a report issued on Friday.
SynCore purchased a 6.09 percent stake in the German company for NT$94 million (US$3.1 million) on May 27 last year.
Chang said the drug would likely hit the market in 2019 and start generating revenue for SynCore in the following year, according to the report.
He forecast sales of the drug would gradually pick up and reach its peak sales of US$512 million in 2024, with SynCore likely receiving 41 percent of the sales as royalties starting in 2020 at NT$61.5 billion.
Global sales for drugs for treating breast cancer are about US$11 billion a year, Chang said.
In addition, SynCore is developing SB04, a drug to treat dry age-related macular degeneration, and Jih Sun Securities estimated sales of the drug would be US$250 million a year in Asia starting 2021, when SynCore launches the drug.
Eyeing the potential sales of the two drugs, Jih Sun Securities rated the company’s shares at “buy.”
The stock is set to shift its listing to the GRETAI Securities Market from the Emerging Stock Market by the end of next month, through issuing 6.87 million new shares with prices tentatively set at between NT$80 and NT$100 per share, according to SynCore.
From January through last month, the company registered revenue of NT$3.13 million on sales of Veregen, a drug licensed from MediGene to treat genital warts caused by human papillomavirus. The company launched the drug in Taiwan in November last year.
In the first six months of this year, the company posted losses of NT$101 million, or NT$1.96 per share, compared with losses of NT$33.23 million, or NT$0.76 per share, the previous year due to higher expenses for research and development, according to the company’s filing to the Taiwan Stock Exchange.
SynCore plans to spend NT$1.05 billion from next year through 2018 to develop SB05 and spend another NT$700 million from this year through 2019 on SB04 research, Chang said.
Leading Taiwanese bicycle brands Giant Manufacturing Co (巨大機械) and Merida Industry Co (美利達工業) on Sunday said that they have adopted measures to mitigate the impact of the tariff policies of US President Donald Trump’s administration. The US announced at the beginning of this month that it would impose a 20 percent tariff on imported goods made in Taiwan, effective on Thursday last week. The tariff would be added to other pre-existing most-favored-nation duties and industry-specific trade remedy levy, which would bring the overall tariff on Taiwan-made bicycles to between 25.5 percent and 31 percent. However, Giant did not seem too perturbed by the
Foxconn Technology Co (鴻準精密), a metal casing supplier owned by Hon Hai Precision Industry Co (鴻海精密), yesterday announced plans to invest US$1 billion in the US over the next decade as part of its business transformation strategy. The Apple Inc supplier said in a statement that its board approved the investment on Thursday, as part of a transformation strategy focused on precision mold development, smart manufacturing, robotics and advanced automation. The strategy would have a strong emphasis on artificial intelligence (AI), the company added. The company said it aims to build a flexible, intelligent production ecosystem to boost competitiveness and sustainability. Foxconn
TARIFF CONCERNS: Semiconductor suppliers are tempering expectations for the traditionally strong third quarter, citing US tariff uncertainty and a stronger NT dollar Several Taiwanese semiconductor suppliers are taking a cautious view of the third quarter — typically a peak season for the industry — citing uncertainty over US tariffs and the stronger New Taiwan dollar. Smartphone chip designer MediaTek Inc (聯發科技) said that customers accelerated orders in the first half of the year to avoid potential tariffs threatened by US President Donald Trump’s administration. As a result, it anticipates weaker-than-usual peak-season demand in the third quarter. The US tariff plan, announced on April 2, initially proposed a 32 percent duty on Taiwanese goods. Its implementation was postponed by 90 days to July 9, then
AI SERVER DEMAND: ‘Overall industry demand continues to outpace supply and we are expanding capacity to meet it,’ the company’s chief executive officer said Hon Hai Precision Industry Co (鴻海精密) yesterday reported that net profit last quarter rose 27 percent from the same quarter last year on the back of demand for cloud services and high-performance computing products. Net profit surged to NT$44.36 billion (US$1.48 billion) from NT$35.04 billion a year earlier. On a quarterly basis, net profit grew 5 percent from NT$42.1 billion. Earnings per share expanded to NT$3.19 from NT$2.53 a year earlier and NT$3.03 in the first quarter. However, a sharp appreciation of the New Taiwan dollar since early May has weighed on the company’s performance, Hon Hai chief financial officer David Huang (黃德才)
RSS